BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting
International Journal of Molecular Sciences · 22.01.2026 · 27 (2) · 1123
DOI: 10.3390/ijms27021123 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.01.2026. Verfasst von João P N Silva und 3 weiteren Autor:innen. Beteiligte Einrichtung: UNIPRO-Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e …. Hauptthemen laut MEDLINE: bcl-X Protein, Neoplasms, Proto-Oncogene Proteins c-bcl-2. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 381 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cooperativa de Ensino Superior Politécnico e Universitário, Fundação para a Ciência e Tecnologia, CESPU—Cooperativa de Ensino Superior Politécnico e Universitário Crl.
Abstract (Originalsprache)
The BCL-2 family of proteins plays a central role in the regulation of apoptosis, with BCL-2 and BCL-xL representing two of its most prominent antiapoptotic members. This review explores the molecular regulation of BCL-2 and BCL-xL genes, emphasizing the structural domains that define the functions of the broader BCL-2 family. Beyond their canonical roles in preventing mitochondrial outer membrane permeabilization, both proteins contribute significantly to cancer development. Their overexpression enhances invasiveness and tumor progression, supports angiogenesis, and critically modulates cellular responses to chemotherapy, often conferring drug resistance. Additional non-apoptotic functions, including roles in metabolism, mitochondrial dynamics, and cellular homeostasis, further expand their biological relevance. Clinical trials exploring strategies to inhibit BCL-2 and BCL-xL, including selective BH3 mimetics and combination regimens, are discussed with emphasis on their potential and limitations in oncology. Overall, this review highlights the multifaceted contributions of BCL-2 and BCL-xL to cancer biology and underscores the importance of continued efforts to refine targeted therapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UNIPRO-Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), 4585-116 Gandra, Portugal.
- Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, Brazil.
- Associate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU, 4585-116 Gandra, Portugal.
- UCIBIO-Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal.
ORCID-Profile: João P N Silva, Bárbara Pinto, Patrícia M A Silva, Hassan Bousbaa
Förderung
- Cooperativa de Ensino Superior Politécnico e Universitário
- Fundação para a Ciência e Tecnologia
- CESPU—Cooperativa de Ensino Superior Politécnico e Universitário Crl
- CESPU
- Fundação para a Ciência e a Tecnologia
Zitieren
APA
Silva, J. P. N., Pinto, B., Silva, P. M. A., & Bousbaa, H. (2026). BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting. International Journal of Molecular Sciences, 27(2), 1123. https://doi.org/10.3390/ijms27021123
Vancouver
Silva JPN, Pinto B, Silva PMA, Bousbaa H. BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting. International Journal of Molecular Sciences. 2026;27(2):1123. doi:10.3390/ijms27021123
BibTeX
@article{Silva2026,
author = {Silva, João P N and Pinto, Bárbara and Silva, Patrícia M A and Bousbaa, Hassan},
title = {BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {2},
pages = {1123},
doi = {10.3390/ijms27021123}
}
EUVIMED